Kiniksa Pharmaceuticals International, plc
KNSA
주식 순위
#3000
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
주가
$78.31
마지막 동기화: 2026-10-16
시가총액
$6.11B
변동 (1일)
-2.04%
변동 (1년)
102.67%
국가
GB
거래 Kiniksa Pharmaceuticals International, plc (KNSA)
카테고리
Healthcare
Kiniksa Pharmaceuticals International, plc (KNSA)의 EPS
June 2026 기준 EPS TTM: $1.07
Kiniksa Pharmaceuticals International, plc의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $1.07입니다. 2023년 말에는 회사의 EPS가 $0.20였으며, 이는 2022년의 EPS $2.64와 감소입니다.
Kiniksa Pharmaceuticals International, plc의 EPS 기록 (2016 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $1.07 | -278.33% |
| 2024 | $-0.60 | -400.00% |
| 2023 | $0.20 | -92.42% |
| 2022 | $2.64 | -214.78% |
| 2021 | $-2.30 | -11.88% |
| 2020 | $-2.61 | -12.71% |
| 2019 | $-2.99 | -14.33% |
| 2018 | $-3.49 | 74.50% |
| 2017 | $-2.00 | 170.27% |
| 2016 | $-0.74 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $2.41 | 125.23% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -98.24% |
HK
|
